An Array co-founder re-emerges as CEO of a small academic spinout, looking to remake an old class of cancer drugs
Tony Piscopio hadn’t worked as a bench scientist in years when, around 2011, he got put in touch with a team at the University of Colorado trying to revitalize an old approach to treating cancer.
Piscopio, who had co-founded Array Biopharma before heading to South Korea to launch a new company, was back in the states, unattached and intrigued. He founded a three-person company with two professors, Xuedong Liu and Gail Eckhardt, and while they worked on the biology side, he returned to his old chemist chair and began drawing up potential compounds on a computer, along with manufacturing processes to make them. Outsourcing companies synthesized or analyzed the results.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.